Comparison of Low Osmolar ORS and ReSoMal for Treating Acute Watery Diarrhea in Severely Malnourished Children Aged 6 Months to 5 Years
NCT ID: NCT07026682
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
72 participants
INTERVENTIONAL
2025-02-10
2025-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This clinical study is being conducted at The Children's Hospital, Lahore, to compare two different types of ORS: low osmolar ORS and ReSoMal (a special rehydration solution designed for malnourished children). The aim is to determine which solution is more effective in correcting low potassium levels (a common problem in these children) and to identify which one has fewer side effects, particularly problems like low or high sodium levels that can be dangerous.
A total of 72 children between 6 months and 5 years of age, all diagnosed with severe malnutrition and mild to moderate dehydration due to acute watery diarrhea, will be included in the study. They will be randomly assigned to receive either low osmolar ORS or ReSoMal. Blood tests will be done before and after the treatment to check for changes in electrolyte levels. The frequency of diarrhea and the child's overall response to treatment will also be recorded.
The hypothesis of this study is that there is a significant difference in both effectiveness and side effects between the two ORS solutions. The results of this study will help doctors choose the safest and most effective ORS for treating diarrhea in severely malnourished children, improving care and potentially saving lives.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management- Surveillance Study for Adverse Effects
NCT00490932
Oral Rehydration Solution With Zinc and Prebiotics in Acute Diarrhea
NCT01025583
Clinical Effectiveness and Safety of a Novel Oral Rehydration Solution
NCT05247879
Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack
NCT00942812
VS002A in the Treatment of Acute Watery Diarrhea in Infants and Young Children
NCT06179589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group-I: Low osmolar ORS. (mmol/L: Na+ 75, K+ 20, Cl- 65, citrate 10, glucose 75, and osmolarity 245) Group-II: ReSoMal ORS. (Na 45 mmol/L, K 40 mmol/L, Cl 76 mmol/L, citrate 7 mmol/L, Mg 6 mmol/L, Zn 300 lmol/ L, Cu 45 lmol/L, glucose 125 mmol/L, osmolarity 300 mmol/L) At arrival in the hospital the dehydration status of the children will be assessed using the dehydration severity score (appendix). The weight of each child along with the height will be noted and I/V lines saved under aseptic measure. Base line investigations including the electrolytes and renal function tests will be sent to the lab and appropriate management of the infection with suitable antibiotics will be started. Fluid deficit will be corrected with 10 mL/kg/h of the assigned ORS given over the first 2 hours, then 5 mL/kg/h over a period of 10 to 12 hours until the deficit is corrected. Ongoing stool losses will be corrected with 5mL/kg after each watery or loose stool. The patients in group-I will receive low osmolar ORS fluid while the patients in group-II will receive standard ORS fluid. 24 hours after the fluid therapy started, blood will be drawn and will be sent for the measurement of electrolytes. The efficacy and side effects will be labelled as per operational definition. The frequency of passage of stool in the 24 hours will also be noted.
All data along will the lab values will be recorded into the attached performa, and all the labs will be done from the hospital lab.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group Low Osmolar ORS
Received low osmolar oral rehydration solution (ORS) with an osmolarity of 245 mmol/L and sodium 75 mmol/L, administered orally according to WHO guidelines for rehydration in diarrhea.
Low Osmolar ORS
Composition: Na⁺ 75 mmol/L, K⁺ 20 mmol/L, Cl- 65 mmol/L, citrate 10 mmol/L, glucose 75 mmol/L; osmolarity 245 mmol/L.
Administered orally in rehydration regimen over 24 hours.
Group ReSoMal
Received ReSoMal oral rehydration solution specifically formulated for malnourished children, with lower sodium and higher potassium content, administered orally.
ReSoMal
Composition: Na⁺ 45 mmol/L, K⁺ 40 mmol/L, Cl- 76 mmol/L, citrate 7 mmol/L, glucose 125 mmol/L, Mg 6 mmol/L, Zn 300 µmol/L, Cu 45 µmol/L; osmolarity 300 mmol/L.
Administered orally over 24 hours according to rehydration protocol.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low Osmolar ORS
Composition: Na⁺ 75 mmol/L, K⁺ 20 mmol/L, Cl- 65 mmol/L, citrate 10 mmol/L, glucose 75 mmol/L; osmolarity 245 mmol/L.
Administered orally in rehydration regimen over 24 hours.
ReSoMal
Composition: Na⁺ 45 mmol/L, K⁺ 40 mmol/L, Cl- 76 mmol/L, citrate 7 mmol/L, glucose 125 mmol/L, Mg 6 mmol/L, Zn 300 µmol/L, Cu 45 µmol/L; osmolarity 300 mmol/L.
Administered orally over 24 hours according to rehydration protocol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both male and female.
* Children presenting with acute watery diarrhea.
* Children have mild to moderate dehydration.
* Children have serum sodium (135-145 mEq/L) and serum Potassium (2.5-3.4 mEq/L).
* Presence of severe malnutrition, defined as weight-for-length ≤ 3 standard deviations from the median of the World Health Organization (WHO) growth standards or mid-upper arm circumference (MUAC) \<115 mm.
* Children tolerating oral fluid.
* Parent or guardian willing and able to provide informed consent for participation.
Exclusion Criteria
* History of chronic gastrointestinal disorders, such as inflammatory bowel disease or celiac disease.
* Received antibiotics within 48 hours before enrollment.
* Children having any systemic illness requiring hospitalization or specific treatment, such as sepsis or pneumonia.
6 Months
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Child Health Sciences and Children's Hospital, Lahore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sadaf Sumreen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sadaf Sumreen
Role: PRINCIPAL_INVESTIGATOR
University Of Child Health Sciences, Lahore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Child Health Sciences, Lahore
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCHSLahore1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.